Special Issue "10th Anniversary of Biomedicines—NAFLD: From Mechanisms to Therapeutic Approaches"

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 15 November 2022 | Viewed by 528

Special Issue Editors

Dr. François R. Jornayvaz
E-Mail Website
Guest Editor
1. Service of Endocrinology, Diabetes, Hypertension and Nutrition, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland
2. Diabetes Center, Geneva University, Rue Michel-Servet 1, 1206 Genève, Switzerland
Interests: NAFLD; NASH; insulin resistance; type 2 diabetes; metabolic syndrome; endocrine diseases
Special Issues, Collections and Topics in MDPI journals
Dr. Karim Gariani
E-Mail Website
Guest Editor
1. Service of Endocrinology, Diabetes, Hypertension and Nutrition, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland
2. Diabetes Center, Geneva University, Rue Michel-Servet 1, 1206 Genève, Switzerland
Interests: NAFLD; NASH; type 2 diabetes; diabetic foot infection
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The year 2022 marks the 10th anniversary of Biomedicines, a peer-reviewed open access journal in the biomedical field. So far, Biomedicines has published more than 2700 papers from more than 17,000 authors. We appreciate each author, reviewer, and academic editor whose support has brought us to where we are today.

To celebrate this significant milestone, we aim to publish a Special Issue entitled 10th Anniversary of Biomedicines—NAFLD: From Mechanisms to Therapeutic Approaches.

NAFLD is the most common cause of chronic liver disease worldwide today, affecting approximately 30% of the general population, and its prevalence continues to increase notably due to the growing obesity epidemic. Therefore, NAFLD is projected to soon become the most common indication leading to liver transplantation in the United States. Moreover, the prevalence of NAFLD can reach 90–95% in obese individuals and affects up to 70% of patients with type 2 diabetes. The estimation of NASH prevalence is more difficult to accurately determine because diagnosis requires a liver biopsy, which is infrequently performed. However, hepatic fibrosis is the only histologic feature of NASH independently associated with long-term overall mortality, liver transplantation, and liver-related mortality. Therefore, it is of crucial importance to better understand the mechanisms leading to the development of NAFLD/NASH and notably fibrosis in order to find therapeutic targets to prevent fibrosis initiation or reverse this process.

We hope that this Special Issue will provide interesting insights into the pathophysiological mechanisms leading to NAFLD/NASH and explore potential therapeutic targets that could be promising over the coming years in the prevalent liver disease.

Dr. François R. Jornayvaz
Dr. Karim Gariani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • NAFLD
  • NASH
  • insulin resistance
  • type 2 diabetes
  • obesity
  • pathophysiological mechanisms
  • therapeutic targets
  • inflammation
  • gut microbiota
  • fibrosis
  • endocrine diseases

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
The Determinants of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Biomedicines 2022, 10(7), 1487; https://doi.org/10.3390/biomedicines10071487 - 23 Jun 2022
Viewed by 234
Abstract
Liver fibrosis is a key pathophysiology process in chronic liver disease. It is still unclear whether the impact of liver fibrosis is not fully realized in type 2 diabetes mellitus (T2D) patients with nonalcoholic fatty liver disease (NAFLD), and the factors affecting nonalcoholic [...] Read more.
Liver fibrosis is a key pathophysiology process in chronic liver disease. It is still unclear whether the impact of liver fibrosis is not fully realized in type 2 diabetes mellitus (T2D) patients with nonalcoholic fatty liver disease (NAFLD), and the factors affecting nonalcoholic steatohepatitis (NASH) or liver stiffness also remain unclear. The aim of this study was to evaluate the determinants of liver fibrosis and in T2D patients with NAFLD. Liver fibrosis and steatosis were measured using transient elastography (FibroScan). Of 226 T2D patients with NAFLD, 50 with liver fibrosis had higher body mass index, serum uric acid, triglyceride and glycated hemoglobin levels and lower high density lipoprotein levels than 176 without liver fibrosis. Multivariate analysis revealed that aging, obesity, sulfonylurea usage and high levels of AST increased the risk of liver fibrosis in T2D patients with NAFLD. Our findings provide useful information to clinical physicians for earlier detection of liver fibrosis in T2D patients with NAFLD and to prevent liver fibrosis through controlling these risk factors. Full article
Show Figures

Figure 1

Back to TopTop